FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and can be used in medicine. Disclosed are novel heterocyclic compounds suitable for increasing the levels of the polypeptide of the transcription factor EB in the cell nucleus in a mammal.
EFFECT: invention can be used for induction of lysosomal biogenesis, as well as in treatment of diseases accompanied by accumulation of pathological aggregates of complex molecules, for example glycosaminoglycans and some other proteins.
8 cl, 7 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| INHIBITORS OF MENIN-MLL INTERACTION | 2017 |
|
RU2829484C2 |
| SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2020 |
|
RU2824583C2 |
| CYTOKINE INHIBITORS | 2008 |
|
RU2485113C2 |
| SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS | 2017 |
|
RU2749038C2 |
| APOPTOSIS-INDUCING AGENTS | 2018 |
|
RU2782469C2 |
| BICYCLIC COMPOUNDS AS PD1/PD-L1 INTERACTION/ACTIVATION INHIBITORS | 2019 |
|
RU2777980C2 |
| CFTR REGULATORS AND THEIR APPLICATION METHODS | 2016 |
|
RU2749834C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2778294C2 |
